Supplemental Discussion
PKA-mediated phosphorylation of PDE3 is reported to increase its activity in platelets and other cells. Since the PKA-mediated phosphorylation and activation of PDE3A during NO stimulation is not described qualitatively or quantitatively it was not included in our model. The impact of this feedback inhibition will be to lower PKA activation, hence be counterproductive for the compartment PKA response to NO. However, at conditions of strong PKA activation, it provides a mechanism for restraining platelet antagonistic responses. Phosphorylation of PDE3A is reported by several kinases in platelets. Thus, PKA, PKC and PKB all phosphorylate and activate PDE3A, albeit at different residues. Unlike PKC phosphorylation, the PKA phosphorylation site do not induce binding of the adaptor proteins 14-3-3, which have been shown to prolong protein phosphorylation through competitive inhibition of phosphatases [1, 2] . In a recent study, PDE3A phosphorylation by different kinases was studied in platelets, showing that cAMP stimulation by forskolin, 8-CPT-cAMP or PGE1 resulted in a 40 % increase in PDE3A activity [3] . At such stimuli, a cAMP level of >20 M has been found, which enables an estimation of PKA activation levels [4, 5] . We have used this information to correct for a realistic level of PDE3 phosphorylation in our twocompartment NO signaling model ( Fig. S2 ). At the PKA activation levels we find in our model, the impact of this phosphorylation seems to be modest. However, as little is known about the distribution of PDE3 in platelets, less is known about possible spatial differences in PDE3 phosphorylation in platelets. In conclusion, we expect PDE phosphorylation to have larger impact at conditions where cAMP-levels increase more dramatically and feedback inhibition serve as an efficient way of lowering platelet inhibition during strong agonistic stimulation. shows the effect of PKA mediated PDE3 phosphorylation at conditions where up to 90 % phospho-PDE3 can be generated (very strong feedback inhibition) (red curves) compared to the PDE3 activity without PKA mediated phosphorylation (black lines). The PDE3 activities at 0 () or 200 nM () cGMP is shown and the conditions of two AC activity levels are illustrated where for the low (1) and medium (2) AC activity the left-shift in steady state cAMP concentration upon introduction of feedback inhibition is illustrated by arrows. Figure S2 . PDE2 models and fit to data from human platelet PDE2. Based on data on human platelet PDE2 from Grant et al. [6] () we tested the performance of two published PDE2 models; Wangorsch et al. [7] (red line) and Zhao et al. [8] (blue line) with the model used in our study (black line). The model by Wangorsch et al. was as we understand it not constructed to account for PDE2 response to cGMP, as cAMP was the focus of the study. Figure S3 . Effect of PKA mediated PDE3 phosphorylation on compartment response to NO. According to recent observation on PDE3 activation in platelets, stimulation of platelets with strongly PKA activating agents (forskolin, 8-CPT-cAMP, or PGE1) resulted in 40% activation of PDE3 [3] . This corresponds to a maximal 20% phosphorylation of PDE3 (3 fold increase in Vmax for PDE3 upon phosphorylation), at these conditions where platelet cAMP levels > 20M can be expected [5] . From this information we calculated the impact of PKA mediated PDE3 phosphorylation and activation on the PKA response of the two-compartment model (4xPDE3, 0.25xPDE2). The original model is shown in black and the model with PDE3 phosphorylation in blue. Open/closed symbols and solid/dotted line denote absence/presence of dipyridamole, respectively.
